Co-Diagnostics is transitioning from a pandemic-driven testing provider to a decentralized molecular diagnostics platform developer. While its proprietary Co-Dx PCR Pro platform holds significant potential for point-of-care and at-home testing, the company remains in a pre-revenue, investment-intensive phase. Following the withdrawal of its initial FDA 510(k) application in late 2024, the timeline for U.S. commercialization remains uncertain. However, international progress, particularly regulatory milestones in India through the CoSara joint venture and strategic partnerships in the Middle East, provides a baseline for long-term growth. Given the high cash burn and reliance on regulatory approvals, a Hold recommendation is warranted until clear commercial traction or FDA clearances are achieved.